<DOC>
	<DOCNO>NCT00902486</DOCNO>
	<brief_summary>This randomize , double blind , placebo control , dose ranging , parallel group study . Subjects active rheumatoid arthritis ( RA ) inadequate response disease modify anti-rheumatic drug ( DMARD ) therapy include biologics enrol . Screening evaluation perform within approximately 28 day randomization . The duration study 6 month primary endpoint assess 3 month . Eligible subject randomly assign one three dos ( 4 , 7 10 mg QD ) INCB028050 placebo .</brief_summary>
	<brief_title>INCB028050 Compared Background Therapy Patients With Active Rheumatoid Arthritis ( RA ) With Inadequate Response Disease Modifying Anti-Rheumatic Drugs</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Must rheumatoid arthritis inadequately control least one DMARD For subject receive antimalarial , must treat antimalarial least 6 month receive stable daily dose For subject receive sulfasalazine , must treat SSZ least 6 month receive stable daily dose 3 gram per day For subject methotrexate , must treat methotrexate least 6 month , receive stable weekly dose methotrexate 10 25 mg For subject leflunomide , must treat leflunomide least 6 month , receive stable dose leflunomide 10 20 mg For subject receive corticosteroid , must dose exceed 10 mg prednisone daily Active rheumatoid arthritis time screen define follow : 6 joint tender painful motion 4 swollen joint least one follow two : ESR great equal 28 mm/hr CRP great equal 10 mg/liter.. Have evidence lack risk tuberculosis Current recent viral , bacterial , fungal , parasitic mycobacterial infection require systemic therapy History infect joint prosthesis Subjects current recent history severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , pulmonary , cardiac , neurological cerebral disease Subjects receive treatment follow drug drug class within specify timeframe : prior treatment rituximab within 12 month , prior treatment oral JAK inhibitor , DMARDs antirheumatic therapy specify allow accord protocol , treatment investigational medication within 12 week 5 halflives ( whichever longer ) , treatment biologic agent within 12 week prior first dose study medication . Subjects past history neutropenia , thrombocytopenia anemia require transfusion time trauma surgery , subject meet protocol specify laboratory measure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
</DOC>